Novartis plans to spin off generics division Sandoz
Sandoz is the last remaining name of the pre-Novartis era. Novartis, founded in 1996, is the product of various mergers over its more than 100 year history.
Keystone / Georgios Kefalas
Swiss pharma firm Novartis has said it plans to spin off its generics and biosimilars division Sandoz into a separate entity to allow both companies to pursue their own growth strategies.
This content was published on
3 minutes
Keystone-SDA/jdp
Español
es
Novartis proyecta escindir la división de genéricos Sandoz
The decision was in the best interest of shareholders, said Novartis CEO Vas Narasimhan in a media call on Thursday.
Late last year the Basel-based company said it was conducting a strategic review of Sandoz and considering all options, including spinning off the company into a separate entity. Many analysts predicted an IPO was the most likely scenario. Sandoz reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but it has seen revenue decline in its key market in the US.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The split will create the largest European generics company and create a “more focused Novartis”, according to a press releaseExternal link.
In April Novartis announced a major restructuring to focus on “innovative medicines” – combining its pharmaceutical and oncology divisions. This led the company to shed 7% of its workforce globally. In Switzerland, it said it would cut 10% of its workforce, which means 1,400 jobs will disappear, many of which are in management positions.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
Since Narasimhan took over the CEO post in 2018, Novartis has been shedding parts of its business. It sold its consumer healthcare unit to GSK and spun off its eyecare division Alcon into a separate entity in 2019.
Future of Sandoz
Sandoz will list on the SIX Swiss Exchange and will remain a Swiss company. However, the specific location of the company’s headquarters has not been determined. Current Sandoz CEO Richard Saynor will continue to lead the company. The board of directors of the future independent company will be formed shortly, Narasimhan added.
No further layoffs are expected at Sandoz as a result of the spin-off. On the contrary, said Narasimhan, “we are currently building up the necessary functions for an independent company”. Further details on the timeline for the spin-off have not been provided.
Novartis is one of the largest pharmaceutical companies in the world. Prior to the recent restructuring, it employed more than 100,000 people worldwide.
More
More
Can Novartis’s sustainability-linked bond make good on its promises?
This content was published on
Novartis’s sustainability-linked bond was a world first for the pharmaceutical industry. But will it improve access to medicine?
As a key maker of antibiotics and off-patent medicines, Sandoz has played a key role in Novartis’ approach to expanding access to medicines in low- and middle-income countries. In an emailed response to SWI, a Novartis company spokesperson said that Novartis remains committed to its global health programs and targets. “The plan is for Sandoz to continue to supply key products to Novartis for distribution in certain key Global Health markets, primarily in Sub-Saharan Africa,” wrote the spokesperson.
Popular Stories
More
Swiss oddities
Mennonite movement turns 500 in Zurich, where it all began
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Zurich laboratory finds intestinal bacteria in coffee machines
This content was published on
Last year, the Zurich Cantonal Laboratory found defects in one in four samples of milk drinks from coffee machines. Too many intestinal bacteria were found in a number of samples.
SWISS Belgrade-Zurich flight forced to land in Germany
This content was published on
Swiss flight LX1413 from Belgrade to Zurich had to make an unscheduled landing today in Friedrichshafen, southern Germany.
New Swiss 3D simulation tool offers better landslide forecasting
This content was published on
A new 3D simulation tool is enabling much more accurate avalanche forecasts. The model, which proved its worth during the landslides in Brienz (GR) and Blatten (VS), could lead to more effective management of alpine risks.
Alleged leader of Kosovar terrorist group indicted in Switzerland
This content was published on
The Office of the Attorney General of Switzerland has brought charges against a Kosovar on suspicion of being the leader of the Swiss branch of a Kosovar terrorist organisation. He is also suspected of having been active in the management of the organisation in Kosovo.
Swiss glacier lake drains without causing flooding damage
This content was published on
The Faverges glacial lake on the Plaine Morte above Lenk in the Bernese Oberland drained over the weekend. There was no flooding or damage, the authorities announced on Monday.
Chihuahua leads Swiss rescue team to owner stuck in a crevasse
This content was published on
A Chihuahua helped to rescue a man on the Fee Glacier above Saas-Fee VS on Friday. It alerted a rescue team to its owner who had fallen into a crevasse.
Swiss bosses distance themselves from the United States
This content was published on
According to a survey of managers, Swiss companies are increasingly turning away from the USA and orientating themselves more towards Southeast Asia and the EU. This is the result of a recent survey.
This content was published on
The Fête de l'Epouvantail (scarecrow festival) is celebrating its 30th anniversary and returns to Denens in canton Vaud for its seventh edition from July 10-20.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.